Evidence map›Paper›PMID 26852128›Full record

ArticleJapanese journal of radiology2016

Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience.

Yukiko Hattori, Taro Murai, Hiromitsu Iwata, Kaoru Uchiyama, Mikio Mimura, Eriko Kato, Rumi Murata, Yuta Shibamoto

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Japanese journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Yukiko HattoriNagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1, Hirate-cho, Kita-ku, Nagoya, Aichi, 462-8508, Japan. yhattori7@yahoo.co.jp.
Taro MuraiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hiromitsu IwataNagoya Proton Therapy Center, Nagoya City West Medical Center, 1-1-1, Hirate-cho, Kita-ku, Nagoya, Aichi, 462-8508, Japan.
Kaoru UchiyamaDepartment of Radiology, Nagoya Daini Red Cross Hospital, 2-9 Myoken-cho, Syowa-ku, Nagoya, Aichi, 466-8650, Japan.
Mikio MimuraDepartment of Radiology, Narita Memorial Hospital, 134, Haneihonmachi, Toyohashi, Aichi, 441-8029, Japan.
Eriko KatoDepartment of Radiology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan.
Rumi MurataDepartment of Radiation Oncology, Suzuka General Hospital, 1275-53, Yamanoue, Yasuzuka-cho, Suzuka, Mie, 513-0818, Japan.
Yuta ShibamotoDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Nagoya City University · JPNagoya Medical Center · JPJapanese Red Cross Nagoya Daini Hospital · JPNational Hospital Organization · JPSuzuka University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposesThe prognosis of localized extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), has improved with the development of chemoradiotherapy. However, conventional extended-field radiotherapy may cause optic disorders. Our group has employed smaller radiation fields in an attempt to avoid toxicity. The efficacy and toxicity of treatments were evaluated. MATERIALS AND

methodsChemoradiotherapy was delivered with a shrinking-field radiotherapy strategy. The endpoints of this study were overall survival (OS), local control (LC), progression-free survival (PFS), and toxicity.

resultsFifteen patients with localized ENKTL were treated. After irradiation (median, 40 Gy) to the tumor plus a prophylactic volume, a reduced treatment volume to the tumor was boosted (median, 10 Gy). Twelve patients underwent chemoradiotherapy and 3 patients received radiotherapy alone. A complete response was achieved in 12 and a partial response in 3 patients. The 5-year OS, PFS, and LC rates were 80, 67, and 93 %, respectively. Distant recurrence occurred in 4 patients and locoregional and distant recurrence in 1 patient. Cataract (grade 3) and dry eye (grade 2) were observed as late adverse events in 1 patient each.

conclusionsSufficiently high OS and LC were achieved with acceptable toxicities. Appropriate target volumes may be smaller with newer chemotherapy regimens.

Indexed as

AdultAgedAged, 80 and overChemoradiotherapyFemaleHumansJapanLymphoma, Extranodal NK-T-CellMaleMiddle AgedNasopharyngeal NeoplasmsNose NeoplasmsRadiation InjuriesRetrospective StudiesTreatment OutcomeExtranodal natural killer/T-cell lymphoma, nasal typeHead and neckLymphomaRadiation therapy

Identifiers

PMID26852128
OpenAlexW2259912622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.